Law360, New York (October 04, 2010, 12:02 PM ET) -- The U.S. District Court for the District in Minnesota held that Ovation Pharmaceutical did not violate federal or state antitrust laws when it acquired Indocin IV and NeoProfen, the only two drugs approved for treatment of patent ductus arteriosus, a specific heart condition that primarily affects low-birthweight, customarily premature babies (FTC v. Lundbeck, Inc., No. 08-6379 and Minnesota v. Lundbeck Inc., No. 08-6381 [D. Minn. Aug. 31, 2010]).
The Federal Trade Commission and Minnesota lost their challenges because they failed to establish that NeoProfen and Indocin...
How Certain Products Can Be The Same, But Different
To view the full article, take a free trial now.
